Shot in the dark: Early COVID-19 vaccine efficacy explained

Typically, regulators strive to have at least 95% certainty that the trial read-out is not the result of random variations with nothing to do with the tested compound. For trial sponsors there is safety in numbers as a large enough trial can ensure that 95% reliability hurdle is cleared.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2K4cUOh
via IFTTT